Cargando…

The Expression of Anti-Müllerian Hormone Type II Receptor (AMHRII) in Non-Gynecological Solid Tumors Offers Potential for Broad Therapeutic Intervention in Cancer

SIMPLE SUMMARY: Until now, only a few studies have examined the AMHRII expression in tumors. Here, with more than 1000 tumor samples and using several complementary techniques we confirmed AMHRII expression in gynecological cancer and demonstrated AMHRII expression in certain non-gynecological cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barret, Jean-Marc, Nicolas, André, Jarry, Anne, Dubreuil, Olivier, Meseure, Didier, Passat, Tilda, Perrial, Emeline, Deleine, Cécile, Champenois, Gabriel, Gaillard, Solenne, Duchalais, Emilie, Ray-Coquard, Isabelle, Lahmar, Mehdi, Dumontet, Charles, Bennouna, Jaafar, Bossard, Céline, Roman-Roman, Sergio, Prost, Jean-François
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8067808/ https://www.ncbi.nlm.nih.gov/pubmed/33917111 http://dx.doi.org/10.3390/biology10040305

Ejemplares similares

Murlentamab, a Low Fucosylated Anti-Müllerian Hormone Type II Receptor (AMHRII) Antibody, Exhibits Anti-Tumor Activity through Tumor-Associated Macrophage Reprogrammation and T Cell Activation
por: Prat, Mélissa, et al.
Publicado: (2021)

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages
por: Bougherara, Houcine, et al.
Publicado: (2017)

Assessment of FSHR, AMH, and AMHRII variants in women with polycystic ovary syndrome
por: Czeczuga-Semeniuk, Ewa, et al.
Publicado: (2014)

The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status
por: Ott, Eva, et al.
Publicado: (2019)

DNA methylation of AMHRII and INSR gene is associated with the pathogenesis of Polycystic Ovary Syndrome (PCOS)
por: Zhong, Xingming, et al.
Publicado: (2021)

The Caspase-1/IL-18 Axis of the Inflammasome in Tumor Cells: A Modulator of the Th1/Tc1 Response of Tumor-Infiltrating T Lymphocytes in Colorectal Cancer
por: Mutala, Linda Bilonda, et al.
Publicado: (2021)

Defining the Immune Checkpoint Landscape in Human Colorectal Cancer Highlights the Relevance of the TIGIT/CD155 Axis for Optimizing Immunotherapy
por: Ducoin, Kathleen, et al.
Publicado: (2022)

Spatial and Temporal Control of Cavitation Allows High In Vitro Transfection Efficiency in the Absence of Transfection Reagents or Contrast Agents
por: Chettab, Kamel, et al.
Publicado: (2015)

Monodisperse polysarcosine-based highly-loaded antibody-drug conjugates
por: Viricel, Warren, et al.
Publicado: (2019)

Expression Profiling of Ribosome Biogenesis Factors Reveals Nucleolin as a Novel Potential Marker to Predict Outcome in AML Patients
por: Marcel, Virginie, et al.
Publicado: (2017)

The cytosolic 5′-nucleotidase cN-II lowers the adaptability to glucose deprivation in human breast cancer cells
por: Bricard, Gabriel, et al.
Publicado: (2017)

Targeting NKG2A to boost anti-tumor CD8 T-cell responses in human colorectal cancer
por: Ducoin, Kathleen, et al.
Publicado: (2022)

Transcriptional and Metabolic Investigation in 5′-Nucleotidase Deficient Cancer Cell Lines
por: Cadassou, Octavia, et al.
Publicado: (2021)

A Tridimensional Model for NK Cell-Mediated ADCC of Follicular Lymphoma
por: Decaup, Emilie, et al.
Publicado: (2019)

Anti-Müllerian Hormone in Pathogenesis, Diagnostic and Treatment of PCOS
por: Rudnicka, Ewa, et al.
Publicado: (2021)

A Proposed Methodology to Deal with the Impact of In Vitro Cellular Matrix on the Analytical Performances of a Targeted Metabolomic LC-HRMS Method
por: Guitton, Jérôme, et al.
Publicado: (2023)

Osimertinib for Front-Line Treatment of Locally Advanced or Metastatic EGFR-Mutant NSCLC Patients: Efficacy, Acquired Resistance and Perspectives for Subsequent Treatments
por: Denis, Marc G, et al.
Publicado: (2020)

Treatments for Non-Small-Cell Lung Cancer: The Multiple Options for Precision Medicine
por: Pons-Tostivint, Elvire, et al.
Publicado: (2022)

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
por: Cobb, Lauren Patterson, et al.
Publicado: (2015)

Clinical application of serum anti-Müllerian hormone in women
por: Oh, So Ra, et al.
Publicado: (2019)

Anti-Müllerian Hormone Signal Transduction involved in Müllerian Duct Regression
por: Cate, Richard L.
Publicado: (2022)

STK11/LKB1 Modulation of the Immune Response in Lung Cancer: From Biology to Therapeutic Impact
por: Pons-Tostivint, Elvire, et al.
Publicado: (2021)

The evolution of Müllerian mimicry
por: Sherratt, Thomas N.
Publicado: (2008)

Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors
por: Heidarpour, Mitra, et al.
Publicado: (2014)

Towards international standardization of immunoassays for Müllerian inhibiting substance/anti-Müllerian hormone
por: Ferguson, Jackie MC, et al.
Publicado: (2018)

Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy
por: Grard, Marion, et al.
Publicado: (2021)

Vaccination against HPV: Easier said than done?
por: Stoeklé, Henri-Corto, et al.
Publicado: (2023)

Anti-Müllerian Hormone: A Valuable Addition to the Toolbox of the Pediatric Endocrinologist
por: Josso, Nathalie, et al.
Publicado: (2013)

ITCH-dependent proteasomal degradation of c-FLIP induced by the anti-HER3 antibody 9F7-F11 promotes DR5/caspase 8-mediated apoptosis of tumor cells
por: Le Clorennec, Christophe, et al.
Publicado: (2019)

Müllerian inhibiting substance/anti-Müllerian hormone: A novel treatment for gynecologic tumors
por: Kim, Jang Heub, et al.
Publicado: (2014)

Müllerian Duct Anomalies and Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome
por: Yang, Min, et al.
Publicado: (2023)

Evaluation of a new automated immunoassay for the quantification of anti-Müllerian hormone
por: Lotierzo, Manuela, et al.
Publicado: (2021)

Persistent mullerian duct syndrome
por: Renu, Divya, et al.
Publicado: (2010)

Primary retroperitoneal mullerian adenocarcinoma
por: Elnemr, Ayman, et al.
Publicado: (2010)

Mediastinal cysts with Mullerian differentiation
por: Miura, Hiroyuki, et al.
Publicado: (2018)

The expression of Müllerian inhibiting substance/anti-Müllerian hormone type II receptor in myoma and adenomyosis
por: Kim, Shin Young, et al.
Publicado: (2018)

Inhibin B and anti-Müllerian hormone/Müllerian-inhibiting substance may contribute to the male bias in autism
por: Pankhurst, M W, et al.
Publicado: (2012)

Anti-Müllerian Hormone Recruits BMPR-IA in Immature Granulosa Cells
por: Sèdes, Lauriane, et al.
Publicado: (2013)

A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models
por: Chettab, Kamel, et al.
Publicado: (2023)

Biopathological Significance of PIWI–piRNA Pathway Deregulation in Invasive Breast Carcinomas
por: Meseure, Didier, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_hrsff0p5cuv4t6mj7vcigdv4go